The potential future role of extensive lipid lowering in ACS patients with the use of PCSK9 inhibitors: early bird catches the worm.

Dimitriadis, Kyriakos; Pyrpyris, Nikolaos; Tsioufis, Konstantinos

Dimitriadis, Kyriakos; Pyrpyris, Nikolaos; Tsioufis, Konstantinos.

Afiliação

Dimitriadis K; First Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens, Hippokration General Hospital, 115 27, Athens, Greece.
Pyrpyris N; First Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens, Hippokration General Hospital, 115 27, Athens, Greece.
Tsioufis K; First Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens, Hippokration General Hospital, 115 27, Athens, Greece.

Eur Heart J Cardiovasc Pharmacother ; 10(2): 85-86, 2024 Feb 23.

Article em En | MEDLINE | ID: mdl-37977850

Assuntos

Anticolesterolemiantes; Inibidores de PCSK9; Humanos; Pró-Proteína Convertase 9; Anticolesterolemiantes/efeitos adversos; Lipídeos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Inibidores de PCSK9 / Anticolesterolemiantes Limite: Humans Idioma: En Revista: Eur Heart J Cardiovasc Pharmacother Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Grécia

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google